Die kontinuierliche subkutane Apomorphingabe

U. M. Fietzek; G. Kavaldjieva; M. Messner; A. Ceballos-Baumann

doi:10.1055/s-0038-1627569

Nervenheilkunde, Table of Contents

Nervenheilkunde 2015; 34(03): 180-186
DOI: 10.1055/s-0038-1627569

Parkinson

Schattauer GmbH

Die kontinuierliche subkutane Apomorphingabe

Ergebnisse einer katamnestischen BefragungThe continuous subcutaneous apomorphine infusion

Authors

U. M. Fietzek

¹Abteilung für Neurologie und klinische Neurophysiologie mit Parkinson-Fachklinik, Schön Klinik München-Schwabing
G. Kavaldjieva

¹Abteilung für Neurologie und klinische Neurophysiologie mit Parkinson-Fachklinik, Schön Klinik München-Schwabing
M. Messner

¹Abteilung für Neurologie und klinische Neurophysiologie mit Parkinson-Fachklinik, Schön Klinik München-Schwabing
A. Ceballos-Baumann

¹Abteilung für Neurologie und klinische Neurophysiologie mit Parkinson-Fachklinik, Schön Klinik München-Schwabing

Abstract

Zusammenfassung

Apomorphin ist der wohl älteste bekannte Dopaminagonist und wird seit langem in der Parkinsontherapie genutzt. Dabei ist die Bolustherapie mit Injektions-Pen von der kontinuierlichen subkutanen Infusion (csAI) zu unterscheiden. Eine Vielzahl von offenen Studien an mehreren hundert Patienten hat die Vorund Nachteile der csAI herausgearbeitet. Die Patientensicht auf dieses ressourcenintensive Verfahren ist nur selten untersucht. Wir stellen die Ergebnisse einer katamnestischen Befragung an 149 Patienten vor, die zwischen 2005 und 2011 eine Apomorphinpumpe an unserer Klinik erhielten. Die csAI wurde mit einer medianen Schulnote von 2,5 (IQR 2,0; 4,0) bewertet. 70,9% der Patienten würden die Therapie weiterempfehlen. Die Entwicklung von subkutanen Noduli war die häufigste berichtete Nebenwirkung bei 55% der Patienten.

Summary

Apomorphine is the oldest synthetic dopamine agonist and has a long tradition in the treatment of Parkinson’s disease. The intermittent bolus injection of apomorphine has to be distinguished from the continuous subcutaneous apomorphine infusion (csAI). A number of open trials has been successful to delineate the benefits and risks of csAI. However, the patients’ view on this resource intensive therapy has seldom been studied in detail. We present the results of a patient audit that was conducted with 149 patients who received the apomorphine pump in between 2005 and 2011. The csAI was given a school grade of 2.5 (IQR 2.0; 4.0). 70.9% of patients would recommend csAI as an treatment option for Parkinson’s disease. Subcutaneous nodules were the most frequently reported adverse effect in 55% of patients.

Schlüsselwörter

Parkinson - Apomorphin - kontinuierliche Therapie - Patientenbefragung

Keywords

Parkinson’s disease - apomorphine - continuous therapy - patient survey

Full Text

References

Literatur
1 Matthiessen A. Researches into the constitution of the opium bases. Part II. On the action of hydrochloric acid on codeia. Proc R Soc Lond 1868; 17: 460-2.
2 Weil E. De l’apomorphine dans certain troubles nerveux. Lyon Méd. Gaz. Médicale J Médecine Réun 1884; 47: 411-9.
3 Millan MJ. et al. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther 2002; 303 (02) 791-804.
4 Cotzias GC. et al. Similarities between neurologic effects of L-dopa and of apomorphine. N Engl J Med 1970; 282 (01) 31-3.
5 Schwab RS, Amador LV, Lettvin JY. Apomorphine in Parkinson’s disease. Trans. Am Neurol Assoc 1951; 56: 251-3.
6 Broussolle E. et al. Relief of akinesia by apomorphine and cerebral metabolic changes in Parkinson’s disease. Mov. Disord. Off. J Mov Disor Soc 1993; 08 (04) 459-62.
7 Ostergaard L. et al. Pen injected apomorphine against off phenomena in late Parkinson’s disease: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 1995; 58 (06) 681-7.
8 Senek M, Nyholm D. Continuous drug delivery in Parkinson’s disease. CNS Drugs 2014; 28 (01) 19-27.
9 Volkmann J. et al. Selecting deep brain stimulation or infusion therapies in advanced Parkinson’s disease: an evidence-based review. J Neurol 2013; 260 (11) 2701-14.
10 Carron R. et al. High frequency deep brain stimulation of the subthalamic nucleus versus continuous subcutaneous apomorphine infusion therapy: a review. J Neural Transm Vienna Austria 2011; 118 (06) 915-24.
11 Antonini A, Odin P. Pros and cons of apomorphine and L-dopa continuous infusion in advanced Parkinson’s disease. Parkinsonism Relat Disord 2009; 15 Suppl 4 S97-100.
12 Chaudhuri KR, Clough C. Subcutaneous apomorphine in Parkinson’s disease. BMJ 1998; 316 7132 641.
13 Colzi A, Turner K, Lees AJ. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1998; 64 (05) 573-6.
14 Deleu D, Hanssens Y, Northway MG. Subcutaneous Apomorphine. Drugs Aging 2004; 21 (11) 687-709.
15 Frankel JP. et al. Subcutaneous apomorphine in the treatment of Parkinson’s disease. J Neurol Neurosurg Psychiatry 1990; 53 (02) 96-101.
16 Gancher ST, Nutt JG, Woodward WR. Apomorphine infusional therapy in Parkinson’s disease: clinical utility and lack of tolerance. Mov Disord Off J Mov Disord Soc 1995; 10 (01) 37-43.
17 García PJRuiz. et al. Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson’s disease with motor fluctuations: a multicenter study. Mov. Disord Off J Mov Disord Soc 2008; 23 (08) 1130-6.
18 De Gaspari D. et al. Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson’s disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus. J Neurol Neurosurg Psychiatry 2006; 77 (04) 450-3.
19 Hughes AJ. et al. Subcutaneous apomorphine in Parkinson’s disease: response to chronic administration for up to five years. Mov Disord Off J Mov Disord Soc 1993; 08 (02) 165-70.
20 Kanovský P. et al. Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: results of a two-year, prospective follow-up. Mov Disord Off J Mov Disord Soc 2002; 17 (01) 188-91.
21 Kreczy-Kleedorfer B. et al. [Long-term results of continuous subcutaneous apomorphine pump therapy in patients with advanced Parkinson disease]. Nervenarzt 1993; 64 (04) 221-5.
22 Manson AJ, Turner K, Lees AJ. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson’s disease: long-term follow-up study of 64 patients. Mov Disord Off J Mov Disord Soc 2002; 17 (06) 1235-41.
23 Morgante L. et al. Continuous apomorphine infusion (CAI) and neuropsychiatric disorders in patients with advanced Parkinson’s disease: a follow-up of two years. Arch Gerontol Geriatr 2004; 38: 291-6.
24 Pietz K, Hagell P, Odin P. Subcutaneous apomorphine in late stage Parkinson’s disease: a long term follow up. J Neurol Neurosurg Psychiatry 1998; 65 (05) 709-16.
25 Poewe Wenning GK. Apomorphine: An underutilized therapy for Parkinson’s disease. Mov Disord 2000; 15 (05) 789-94.
26 Pollak P. et al. Subcutaneous apomorphine in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1989; 52 (04) 544.
27 Stibe C, Lees A, Stern G. Subcutaneous infusion of apomorphine and lisuride in the treatment of parkinsonian on-off fluctuations. Lancet 1987; 01 8537 871.
28 Stocchi F. Use of apomorphine in Parkinson’s disease. Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol 2008; 29 Suppl 5 S383-6.
29 Tyne H. et al. A 10 year retrospective audit of longterm apomorphine use in Parkinson’s disease. J Neurol 2004; 251 (11) 1370-4.
30 Wolters E. et al. Managing Parkinson’s disease with continuous dopaminergic stimulation. CNS Spectr 2008; 13 4 Suppl 7 1-14.
31 Poewe W. et al. Continuous subcutaneous apomorphine infusions for fluctuating Parkinson’s disease. Long-term experience in 20 patients. Neurology 1991; 41 3/S1 172-3.
32 Todd A, James CA. Apomorphine nodules in Parkinson’s disease: best practice considerations. Br J Community Nurs 2008; 13 (10) 457-63.
33 Poltawski L. et al. Ultrasound treatment of cutaneous side-effects of infused apomorphine: A randomized controlled pilot study. Mov Disord 2009; 24 (01) 115-8.
34 Acland KM. et al. Panniculitis in association with apomorphine infusion. Br J Dermatol 1998; 138 (03) 480-2.
35 Ganesalingam J, Bain P. Apomorphine-induced necrotic ulcers. Mov Disord 2011; 26 (12) 2182-2182.
36 Pot C. et al. Apomorphine-induced eosinophilic panniculitis and hypereosinophilia in Parkinson disease. Neurology 2005; 64 (02) 392-3.
37 Di Rosa AE. et al. Continuous apomorphine infusion and neuropsychiatric disorders: a controlled study in patients with advanced Parkinson’s disease. Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol 2003; 24 (03) 174-5.
38 Alegret M. et al. Comparative cognitive effects of bilateral subthalamic stimulation and subcutaneous continuous infusion of apomorphine in Parkinson’s disease. Mov Disord 2004; 19 (12) 1463-9.
39 Ondo WG. et al. Apomorphine Injections: Predictors of initial adverse effects. Mov Disord 2010; 25 S2 S181-565.
40 Simons JA. et al. Development and validation of a new screening questionnaire for dysphagia in early stages of Parkinson’s disease. Parkinsonism Relat Disord 2014; 20 (09) 992-8.